Skip to content
DataLookout
Menu

NCT06641388

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects

StatusUnknown
PhasePhase 1
SponsorAkeso
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Area under curve (AUC)
Timeframe: Baseline till last follow-up visit( up to day 43 or day 57)
Maximum (peak) plasma concentration (Cmax)
Timeframe: Baseline till last follow-up visit( up to day 43 or day 57)
Incidence of adverse events(AE)
Timeframe: From the time of signing the informed consent form till last follow-up visit( up to day 43 or day 57)

Secondary (4)

Free protein convertase of proprotein convertase subtilisin/kexin type 9 (PCSK-9)
Immunogenicity index
PCSK-9 concentration
Serum Low-density lipoprotein Cholesterol (LDL-C) concentration

Arms and interventions

Ebronucimab 150mg (after the change)Experimental

Ebronucimab 150mg Single subcutaneous injection into the abdomen.

Ebronucimab 150mg (before the change)Experimental

Ebronucimab 150mg Single subcutaneous injection into the abdomen.

Drugs: Ebronucimab

Sites

1 site in 1 country

  • The Third Xiangya Hospital of Central South UniversityChangsha, Hunan, China